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Modulatory effects of perindopril on cisplatin-induced 
nephrotoxicity in mice: Implication of inflammatory cytokines 
and caspase-3 mediated apoptosis
Cisplatin-induced nephrotoxicity limits its anticancer 
effectiveness, thus this study’s aim was to assess the 
potential modulatory effect of perindopril on cisplatin- 
-induced nephrotoxicity and to elucidate the possible 
underlying mechanisms. Renal dysfunction was 
indu ced in mice by a single injection of cisplatin 
(10 mg kg–1, i.p.) and perindopril was administered 
orally (2 mg kg–1, once daily) for 5 days. Perindopril 
remarkably ameliorated cisplatin-induced perturba-
tions in renal histology, renal levels of tumor necrosis 
factor-alpha, interleukin-6 and interleukin-10, apop-
tosis-regulating protein expressions (Bax and Bcl2), 
and partially normalized Bax to Bcl2 ratio and active 
caspase 3 protein expression. Conversely, perindopril 
had no significant effect on cisplatin-induced eleva-
tions in serum creatinine and urea, microalbumin-
uria, kidney to body weight ratio, lipid peroxidation 
marker, superoxide dismutase and catalase activities 
and reduced glutathione content. In conclusion, perin-
dopril may be safely used with cisplatin in mice since 
it ameliorated cisplatin-induced histopathological 
changes, inflammation and apoptosis without affect-
ing renal biomarkers or oxidative stress.
Keywords: perindopril, cisplatin, nephrotoxicity, oxidative 
stress, apoptosis, inflammation
Cisplatin is a chemotherapeutic drug clinically effective against various types of malig-
nancies. However, due to frequent adverse effects including bone marrow suppression, neuro-
toxicity, ototoxicity, and notably nephrotoxicity, its clinical utility has been hampered (1). The 
major excretion route of cisplatin is renal. Cisplatin accumulates in the renal tissue resulting 
in necrosis of the proximal renal tubules and apoptosis in the distal nephron (2). About 30 % 
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of patients receiving high-dose cisplatin have experienced severe renal dysfunction (3). 
 Cisplatin has been reported to injure several renal structures including blood vessels, 
 glomeruli, and most commonly the renal tubules (4). Clinical reports show that cisplatin- 
-induced renal toxicity often results in acute renal failure, which is characterized by declines 
in renal blood flow within 3 hours of cisplatin administration and decreased glomerular 
filtration rate (5). Other complications, namely elevated levels of serum creatinine and blood 
urea nitrogen, have also been reported in both acute and chronic cisplatin-induced renal 
toxicity (6). Several experimental studies suggest a sequential injury pathway in cisplatin- 
-induced renal toxicity, particularly conversion to toxic metabolites, induction of nuclear and 
mitochondrial DNA damage, oxidative stress and mitochondrial dysfunction, induction of 
inflammation and activation of apoptotic pathway (7, 8). Prevention of cisplatin-induced 
nephrotoxicity reduces complications and may allow administration of a higher dose of 
cisplatin with added therapeutic potential. Clinical approaches to improve cisplatin- 
-induced-nephrotoxicity have been ongoing, however, there is no optimal protective agent. 
Therefore, it is pertinent to develop a therapy to limit the cisplatin-induced nephrotoxicity 
that might target one or more of cisplatin-nephrotoxic pathways (9). Many patients who are 
receiving cisplatin might be using additional drugs to control other diseases such as hyper-
tension for which angiotensin-converting enzyme inhibitors (ACEIs) are the first-line choice. 
Studies on interactions between cisplatin and ACEIs drugs are limited.
Perindopril is an oral ACEI prodrug that results in decreased plasma angiotensin II 
level, decreased vasoconstriction, and decreased aldosterone secretion (10). Perindopril is 
approved for the treatment of hypertension, arterial stiffness, left ventricular hypertrophy, 
post-myocardial infarction and reduction of albuminuria in patients with hypertension 
and nephropathy or diabetes mellitus (10, 11). Accumulated evidence suggests the role of 
localized renin-angiotensin system (RAS) in the progression of different pathologies. RAS 
stimulation mediates oxidative and inflammatory damage, mostly via activation of 
NADPH oxidase and the inhibition of endothelial nitric oxide synthase (12, 13). Interest-
ingly, interference with localized RAS in different animal models using ACEIs was shown 
to offer protective effects in the liver (14), respiratory tract (15), joints (16) and the brain (13). 
The aim of the present study was to examine the possible modulatory effects of perindo-
pril on cisplatin-induced acute nephrotoxicity in mice and the potential mechanisms 
 behind this modulation.
EXPERIMENTAL
Chemicals
Cisplatin and perindopril were purchased from Sigma-Aldrich (USA).
Animals
Male Swiss albino mice, weighing 25–30 g, were purchased and housed within the 
animal facility at Faculty of Pharmacy, Al-Azhar University. Animals care, treatment and 
sampling were executed in agree with the National Institutes of Health guide for the care 
and use of laboratory animals (NIH Publications No. 8023, revised 1978).
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Design of the work
Mice were randomly assigned to four groups (8 mice each) as follows: 1. Control 
group: injected i.p. with saline (0.1 mL per 20 g body mass) once daily for 5 consecutive 
days; 2. Perindopril group: mice treated orally with perindopril (2 mg kg–1, once daily) 
for 5 consecutive days (17, 18); 3. Cisplatin group: mice injected i.p. with a single dose of 
cisplatin (10 mg kg–1) (19, 20); 4. Cisplatin + perindopril group: mice treated with perin-
dopril for 5 days starting 1 h before cisplatin (doses as above). The first day of drug treat-
ment was considered day zero. On day 5, all animals were weighed, then euthanized and 
the serum samples were collected for the assessment of kidney functions. Urine samples 
were collected at end of experiment and centrifuged (2000 g at 4 °C for 15 min) after which 
the supernatant was used for the assessment of microalbuminuria. Both kidneys from 
each animal were collected and weighed to calculate relative kidney mass to body mass. 
Portions of the kidneys were rapidly stored at −80 °C until analyses were performed. 
 Another portion of the kidney was placed immediately in 10 % neutral buffered formalin 
for histopathological and immunofluorescence examinations. 
Evaluation of kidney status
Serum renal biomarkers and microalbuminuria. – Sera were carefully separated from fresh 
blood samples and used for determination of serum kidney function markers (creatinine 
and urea) using colorimetric diagnostic kits according to the manufacturer’s instructions 
(Biodiagnostic Ltd., UK). In addition, microalbuminuria was measured according to the 
manufacturer’s instructions (Biosystems, Spain).
Histopathological evaluation of kidney. – A portion of kidney was rinsed with ice-cold 
saline then embedded in 10 % neutral-buffered formalin for 48 h. Samples were dehy-
drated by alcohol, cleared by xylol, and finally embedded in paraffin blocks. Paraffin- 
- embedded specimens were cut into sections of 4–6 microns thickness, placed on poly-
lysine coated slides. Slides were deparaffinized, rehydrated with ethanol, rinsed in 
distilled water and stained with hematoxylin and eosin (H&E) before microscopical 
 examination (Leica Imaging Systems, UK). 
Determination of oxidative stress markers
Renal tissues were weighed and homogenized (1:10, m/V) in phosphate-buffered 
 saline (pH 7.4), then centrifuged (2000 g at 4 °C) for 15 min and the supernatant was used 
to measure oxidative stress biomarkers. Renal content of malonaldehyde (MDA), reduced 
glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) were evaluated in the 
whole tissue homogenate and normalized to the protein content in each sample using com-
mercial kits (Bio-Diagnostics, Egypt).
Measurement of renal tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)  
and interleukin-10 (IL-10)
Supernatants of renal tissues homogenates were used to measure TNF-α using Mouse 
TNF-α ELISA Kit (Sigma-Aldrich Co, USA), IL-6 using mouse IL-6 ELISA kit (RayBiotech, 
Inc., USA) and IL-10 using mouse IL-10 ELISA kit (Cusabio Technology LLC, USA) accord-
ing to the manufacturer’s instructions.
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Immunofluorescent assay of renal Bax, Bcl2 and active caspase 3 proteins
Immunofluorescent staining was performed to determine the differences in immuno-
reactivity intensity of Bax, Bcl2 and Caspase 3 proteins in renal tissues collected from mice 
allocated to different treatment groups. Briefly, tissue sections were deparaffinized in 100 
% xylene and rehydrated through a graded ethanol series. Antigen retrieval was per-
formed by incubating the tissue sections for 20 min in 0.01 mol L–1 sodium citrate buffer, 
pH 6.0, in a microwave oven. Briefly, the samples were initially boiled in a microwave at 
800 W for 3 min, then for 7 min at 400 W to continue boiling. After cooling down for 30 min 
at room temperature (25 °C), the 10-min heating procedure was repeated with fresh buffer. 
Next, the sections were treated with blocking buffer [1 % horse serum in PBS] for 1 h. 
 Tissue sections were incubated overnight at 4 °C in a humidified chamber with the  primary 
antibodies; Bax (1: 250; Santa Cruz Biotechnology, USA), Bcl2 (1: 250; Santa Cruz Biotech-
nology), and Active Caspase 3 (1: 250; Santa Cruz Biotechnology). After washing, bound 
antibodies were detected by Texas Red labeled goat anti-mouse secondary antibodies 
(Thermo Fisher Scientific, USA). Nuclei were stained with DAPI and slides were mounted 
in Fluoromount G. The specificity of the immunoreaction was confirmed by incubation 
with PBS instead of the primary antibodies. The evaluation was performed by Nikon 
 fluorescence microscope (Nikon eclipse 90i with a DS-U3 imaging system, Nikon Metro-
logy, Inc., USA) under blue, green, and red channels. Fluorometric density analysis was 
performed using ImageJ/NIH software (National Institute of Health, USA). Fluorometric 
intensities of nine microscopic fields with exact areas and same resolutions were measured 
for each tissue section. Data represented as mean ± SD (n = 8). 
Statistical analysis
Data were presented as means ± standard deviation (SD). Graphpad prism V5 (Graph-
pad Prism Software Inc., USA) was used to perform the one-way analysis of variance 
(ANOVA) followed by Tukey’s post hoc test. Statistical significance was accepted at p < 0.05.
RESULTS AND DISCUSSION
Effect of perindopril on kidney status
Cisplatin caused significant elevations in serum creatinine, urea and microalbumin-
uria by 4.6, 10.8 and 2.3 folds of control group respectively (Table I). Administration of 
perindopril in cisplatin-treated mice had no significant effect on renal dysfunction  induced 
by cisplatin since the levels of serum creatinine, urea and microalbuminuria were still 
significantly elevated at 4.3, 11 and 2.7 folds of control group respectively (Table I).
The kidney mass to body mass ratio was significantly increased by cisplatin to 1.3 fold 
of the control group (Table I). Perindopril was unable to correct cisplatin-induced elevation 
in the ratio of kidney mass to body mass.
In addition to kidney mass to body mass ratio, histopathological examination using 
H&E stain revealed normocellular glomeruli and patent tubular lumen lined by cuboidal 
epithelium normal kidney architecture in control and perindopril groups (Fig. 1). In the 
cisplatin group, there was marked vacuolar alteration of the tubular epithelium with 
 occasional tubular cystic dilatation filled with hyaline casts (Fig. 1). Cotreatment with 
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 perindopril caused regression of these structural changes as shown by mild glomerular 
hypercellularity, vacuolar alteration of the tubular epithelium with occasional hyaline 
casts and scattered interstitial mononuclear inflammatory cell infiltrate (Fig. 1).
Based on these results, cisplatin-induced acute nephrotoxicity was documented in 
this study via elevation of serum creatinine and urea in addition to microalbuminuria, 
histopathological perturbations of kidney tissues and kidney hypertrophy as indicated by 
the increase in kidney mass to body mass ratio. Interestingly, perindopril administration 
for 5 days had partially ameliorated cisplatin-induced nephrotoxic effect which was docu-
mented in histological analysis of renal tissue sections. Conversely, using perindopril for 
Table I. Effect of perindopril on cisplatin-induced changes in renal biomarkers
Control Perin Cis Cis + Perin
Serum creatinine (mg dL–1) 0.17 ± 0.05 0.13 ± 0.04 0.78 ± 0.20* 0.73 ± 0.12a
Serum urea  (mg dL–1) 26.33 ± 4.18 25 ± 3.74 284.33 ± 33.60* 290 ± 14.14a
Microalbuminuria (mg L–1) 300 ± 53.57 221.67 ± 23.17 700 ± 82.28* 800 ± 78.99a
% KM/BM 1.20 ± 0.12 1.21 ± 0.10 1.58 ± 0.20* 1.66 ± 0.23a
Renal dysfunction was induced in mice by a single cisplatin (Cis) injection (10 mg kg–1, i.p.). Perindopril (Perin) was 
administered orally (2 mg kg–1, once daily) for 5 days starting 1 h before Cis injection; and then serum creatinine, 
serum urea, microalbuminuria and percentage of kidney mass from total body mass (% KM/BM) were measured. 
Data are represented as mean ± SD (n = 8); a significant difference from the control group (p < 0.05); using ANOVA 
followed by Tukey’s post hoc test.
Fig. 1. Effect of perindopril on cisplatin-induced changes in kidney histopathology. Renal dysfunc-
tion was induced in mice by a single cisplatin (Cis) injection (10 mg kg–1, i.p.). Perindopril (Perin) was 
administered orally (2 mg kg–1, once daily) for 5 days starting 1 h before Cis injection. H&E stain of 
renal tissue sections revealed normocellular glomeruli and patent tubular lumen lined by cuboidal 
epithelium normal kidney architecture in control and Perin groups. In the Cis group, marked vacu-
olar alteration of the tubular epithelium with occasional tubular cystic dilatation filled with hyaline 
casts. Cis+Perin group showed mild glomerular hypercellularity, vacuolar alteration of the tubular 
epithelium with occasional hyaline casts and scattered interstitial mononuclear inflammatory cell 
infiltrate.
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a longer period (14 days vs. 5 days in our study) in a rat model of acute cisplatin-induced 
nephrotoxicity showed protective effect of perindopril on cisplatin-induced serum renal 
biomarkers and kidney hypertrophy (21). Collectively, it is plausible that perindopril had 
no deteriorating effect on cisplatin-induced nephrotoxicity and it may require more time 
to reflect the improvement in renal functions.
Effect of perindopril on oxidative stress
Experimental evidence has indicated the basic role of oxidative stress in the pathogen-
esis of cisplatin-induced nephrotoxicity (22, 23). In our study, cisplatin had induced oxida-
tive stress in renal tissue which is manifested by increased level of lipid peroxidation 
marker (MDA) to 2.0 folds of control group (Fig. 2d) and attenuation of both enzymatic 
(SOD and CAT) and non-enzymatic antioxidant defense (GSH) to 0.7, 0.5 and 0.5 folds of 
control group respectively (Fig. 2a-c). Coadministration of perindopril with cisplatin 
 resulted in non-significant changes in these oxidative stress markers. Conversely, previous 
studies showed antioxidant activities for perindopril (21, 24). This might be due difference 
in disease model and treatment.
Fig. 2. Effect of perindopril on cisplatin-induced renal oxidative stress. Renal dysfunction was in-
duced in mice by a single cisplatin (Cis) injection (10 mg kg–1, i.p.). Perindopril (Perin) was adminis-
tered orally (2 mg kg–1, once daily) for 5 days starting 1 h before Cis injection. Renal tissue activity of: 
a) SOD and b) catalase in addition to c) GSH and d) MDA content were measured. Data represented 
as mean ± SD (n = 8). * indicates a significant difference from the control group (p < 0.05); using 
ANOVA followed by Tukey’s post hoc test.
a)                                                          b)
c)                                                          d)
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Effect of perindopril on inflammatory markers
In addition, induction of inflammation has been also implicated in cisplatin-induced 
renal tissue injury (1, 4, 8). The current work has demonstrated that cisplatin had signifi-
cantly elevated proinflammatory cytokines TNF-α and IL-6 in renal tissue to 5.7 and 7.9 
folds of control group respectively (Fig. 3a,b). Furthermore, cisplatin significantly decre-
ased the renal level of the antiinflammatory cytokine IL-10 to 0.4 folds of control group 
(Fig. 3c). Treatment with perindopril ameliorated cisplatin-induced inflammatory pathway 
as indicated by the decrease in the levels of TNF-α and IL-6 to 2.3 and 3.6 folds respec-
tively and the elevation of IL-10 to 1.6 folds of control group value. Perindopril treatment 
in control mice had no significant effect on these inflammatory cytokines.
Fig. 3. Effect of perindopril on cisplatin-induced changes in renal levels of TNF-α, IL-6 and IL-10. 
Renal dysfunction was induced in mice by a single cisplatin (Cis) injection (10 mg kg–1, i.p.). Perindo-
pril (Perin) was administered orally (2 mg kg–1, once daily) for 5 days starting 1 h before Cis injection; 
and then: a) TNF-α b) IL-6 and c) IL-10 were measured in renal tissue total homogenate. Data repre-
sented as mean ± SD (n = 8). *or # indicates a significant difference from control or Cis groups respec-
tively (p < 0.05); using ANOVA followed by Tukey’s post hoc test.
It is documented that the induction of oxidative stress could induce inflammation of 
somatic cells (25, 26). However, in our study, perindopril alleviated cisplatin-induced 
 inflammation without affecting cisplatin-induced oxidative stress, suggesting that the 
 antiinflammatory effect of perindopril is independent from its antioxidant effect.
Effect of perindopril on markers of apoptosis
Both inflammation and oxidative stress have been associated with caspase-dependent 
renal cellular apoptosis (25, 27–29). Our study indicated that cisplatin administration has 
significantly increased the expression of the proapoptotic Bax protein 4.8 folds of control 
group (Fig. 4a and 4c) and significantly decreased anti-apoptotic protein Bcl-2 level to 0.3-
fold of control group (Fig. 4b and 4d) and hence, the Bax to Bcl2 ratio was significantly 
increased to 3.6 folds of control (Fig. 4e). Increased Bax to Bcl2 ratio may favor the release 
of cytochrome c and could have led to the significant increase in active caspase-3 protein 
expression in renal tissues (30–32), which was confirmed by our results whereas, cisplatin 
had induced a significant increase in the expression of active caspase 3 to 14.32 folds of 
control (Fig. 5a,b). These events could significantly contribute to renal cell death, which 
a)                                                   b)                                                c)
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was further confirmed by histopathological investigation, changes in renal to body mass 
ratio and reduced renal function. 
Interestingly, coadministration of perindopril with cisplatin significantly has de-
creased the expression of Bax and caspase-3 proteins to 2.5 and 7.0 folds of control respec-
tively and has increased the antiapoptotic protein Bcl2 to 0.4 folds of control and remark-
ably normalized BAX to Bcl2 ratio, highlighting its abatement on apoptotic activity and 
reinforcing its potential protective effect against cisplatin-induced renal injury.
It is worth mentioning that our study examined the potential interaction between 
cisplatin and perindopril in a murine model. Although both drugs are commonly used in 
Fig. 4. Effect of perindopril on cisplatin-induced changes in the expression of renal BAX and BCL2 
proteins. Renal dysfunction was induced in mice by a single cisplatin (Cis) injection (10 mg kg–1, i.p.). 
Perindopril (Perin) was administered orally (2 mg kg–1, once daily) for 5 days starting 1h before Cis 
injection; and then BAX and BCL2 were measured. a) representative BAX immunofluorescence im-
ages, b) representative BCL2 immunofluorescence images, c) BAX quantification, d) BCL2 quantifica-
tion, e) ratio of BAX to BCL2. The fluorometric intensity of at least nine microscopic fields was mea-
sured for each tissue section. Data represented as mean ± SD (n = 8). *, # indicate a significant difference 
from control and Cis groups respectively (p < 0.05); using ANOVA followed by Tukey’s post hoc test.
a)                                                                                  c)
                                                                                    d)
                                                                      
b)
 
                                                                                   e)
                                                                              e)
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clinical situations, only a single study in a different model has examined this interaction 
(21), possibly during our study timeframe. The underlying mechanism behind this interac-
tion was partially elucidated in our study including the amelioration of cisplatin-induced 
inflammation and apoptosis of renal cells. However, oxidative stress was not affected by 
perindopril which is in contrast with the previously mentioned study (21). Further studies 
are required on this interaction using a different animal model and different dose levels 
for longer duration to gain more data.
CONCLUSIONS
Perindopril may be safely used with cisplatin in mice. Perindopril ameliorated cisplatin- 
-induced acute renal injury via abrogation of cisplatin-induced inflammation in renal cells 
and apoptosis without affecting oxidative stress or renal biomarkers. 
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